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Extended Infusions of Meropenem for Febrile Neutropenia
Daniel J Przybylski, PharmD and David J Reeves, PharmD, BCOP
Abstract:
Background: Neutropenic fever is an oncologic emergency that requires quick intervention with anti-pseudomonal beta-lactam
antibiotics, such as meropenem. Previous literature suggests that extended infusions of beta-lactam antibiotics may improve clinical
outcomes. To date, there are 3 prior studies utilizing an extended infusion beta-lactam in this population; however, there is only one
previous study investigating the use of extended infusion meropenem in patients with febrile neutropenia.
Objective: To describe the outcomes of eight patients receiving extended infusions of meropenem for the treatment of febrile
neutropenia.
Methods: A retrospective chart review was completed including adult patients admitted to a community teaching hospital who received
extended infusions of meropenem for febrile neutropenia.
Results: In this descriptive study, no patients receiving extended infusions of meropenem failed treatment, were readmitted for an
infectious issue within 30 days, or endured inpatient mortality. Additionally, all eight patients defervesced within 48 hours, and four
patients had a microbiologically documented infection. One patient incurred Clostridium difficile on day 2 of meropenem therapy.
Conclusions: Extended infusions of meropenem may be effective in the treatment of febrile neutropenia. Future studies comparing
extended infusions to intermittent infusions of meropenem for febrile neutropenia are warranted.

INTRODUCTION
Febrile neutropenia is a complication of cancer treatment and
requires the use of broad spectrum antibiotics to treat
potentially life-threatening infections. Anti-pseudomonal betalactam antibiotics such as cefepime, piperacillin/tazobactam, or
meropenem are first-line options in the treatment of febrile
neutropenia.1 In general, efficacy for all beta-lactam antibiotics
is enhanced when the concentrations of the antibiotics are four
to five times greater than the organism’s minimum inhibitory
concentration (MIC).2 In order to achieve favorable clinical
outcomes, carbapenems (such as meropenem) require the time
above the MIC to be at least 30-40% of the dosing interval.2
Traditionally, meropenem is given every 6 or 8 hours with a
standard 30 minute infusion to achieve this time above the MIC
outcome; however, a Monte Carlo simulation in critically ill
patients with febrile neutropenia with bacteremia suggests that
extended infusions of meropenem increase its time above the
MIC and thus the probability of target attainment (PTA)
indicating extended infusions may have utility in the febrile
neutropenia population.3
Although this administration method seems like a promising
alternative to the current standard, there is little clinical literature
to support its use in the high risk setting of febrile neutropenia.
Furthermore, the use of extended infusions renders the
intravenous line unavailable for other medications, which is
particularly problematic in those receiving several intravenous
medications. Previously, a prospective study from 2017 in
neutropenic patients compared extended and standard
infusions of cefepime and found that there were comparable
outcomes in regards to defervescence at 72 hours, clinical
success, mortality, and length of stay.4 Of note, this prospective
study demonstrated a potential decrease in the time to
defervescence. In another retrospective trial of cefepime,

patients receiving extended infusions were more likely to
defervesce at 24 hours and time to defervescence was decreased
by 14 hours compared to standard 30-minute infusions.5
Likewise,
piperacillin/tazobactam
extended
infusions
demonstrated increased overall response (resolution of fever,
sterile blood cultures, resolution of clinical signs and symptoms,
and no need for change in antibiotic regimen) on day 4 in
patients with febrile neutropenia.6 In the only published study
evaluating extended infusions of meropenem for febrile
neutropenia, treatment success after 5 days of meropenem was
higher in those receiving the extended infusion.7 However, this
study was limited to patients undergoing hematopoietic stemcell transplantation or induction chemotherapy for acute
myeloid leukemia (AML). Data in the general oncology
population with febrile neutropenia is lacking. The purpose of
this retrospective, observational study is to describe the
outcomes of extended infusion meropenem in patients with
febrile neutropenia due to any cause.

METHODS
Study patients
The local Institutional Review Board approved this retrospective,
single center study. Adult patients admitted to a community
teaching hospital with febrile neutropenia (ANC <500 cells and
temperature ≥100.5° F) from August 2013 to March 2017 were
included in this study if they received extended infusions of
meropenem. Patients were excluded if defervescence occurred
before meropenem was initiated. Per hospital protocol, patients
receiving extended infusions received their first dose of
meropenem over 30 minutes and subsequent doses were
administered over 3 hours. If a patient incurred more than one
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episode of febrile neutropenia during their hospital stay (i.e.,
became febrile after meeting criteria for defervescence – see 2.2
Data collection below), only the first episode was included in this
analysis.

dialysis. Creatinine clearance was determined using the
Cockcroft-Gault equation.

Data collection

A total of eight patients were included in this descriptive study.
Of these eight patients, five were female and three were male.
Patient age ranged from 51 to 76 years and creatinine clearance
ranged from 40 to 90 mL/min. Additionally, two patients
received prophylaxis with ciprofloxacin, two patients received
prophylaxis with sulfamethoxazole/trimethoprim, and the other
four patients did not receive antibiotic prophylaxis. One patient
received suboptimal renal dosing of meropenem. Additional
patient characteristics are described in Table 1. Six of the eight
patients had an oncologic diagnosis, one patient had
myasthenia gravis, and the other patient had a history of kidney
transplant and was receiving immunosuppressants. Table 2
encompasses all patient diagnoses and their chemotherapy
regimens, if applicable.

Demographic and clinical characteristics collected from the
electronic health record for all eligible patients included age, sex,
length of stay, serum creatinine, height, weight, documented
past medical history, oncology diagnosis, duration of
neutropenia, receipt of prior chemotherapy, use of prophylactic
antibiotics, presence of documented mucositis, concomitant
intravenous vancomycin usage, granulocyte colony stimulating
factor (GCSF) administration, defervescence, time to
defervescence, readmission within 30 days for an infectious
issue, inpatient mortality, microbiologically documented
infection, and antibiotic failure. Defervescence was defined as a
temperature ≤100.4° F for at least 24 hours. Time to
defervescence was defined as time from initiation of
meropenem until defervescence. Antibiotic failure was defined
as switching to another antibiotic for any reason other than
allergy/intolerance or inpatient mortality due to febrile
neutropenia. Additionally, Charlson Comorbidity Index Score
and optimal renal dosing were determined for each patient.
Optimal renal dosing was defined as meropenem 500 mg every
6 hours for a creatinine clearance ≥50 ml/min, meropenem 500
mg every 8 hours for a creatinine clearance between 25 and 49
ml/min, meropenem 500 mg every 12 hours for a creatinine
clearance between 10 and 24 ml/min, and meropenem 500 mg
every 24 hours for a creatinine clearance ≤10 ml/min or on

RESULTS

No patients failed antibiotics, were readmitted for an infectious
issue, or died during their hospital admission. Length of stay
ranged from 4 to 53 days and time to defervescence ranged
from 4 to 40.5 hours (average 21.6 hours). Four patients had a
microbiologically documented infection, one of which incurred
bacteremia. No patients experienced any adverse effects
requiring meropenem discontinuation. Further patient
outcomes and a description of microbiologically documented
infections are described in Table 3 and Table 4, respectively.

Table 1: Patient Characteristics
Patient number

1

2

3

4

5

6

7

Male

Female

Female

Female

Male

Female

Female

Male

Age, years

69

51

65

64

72

60

55

76

Weight, kg

85

72

60

105

92

56

87

96

Baseline CrCl, mL/min

58

71

45

81

69

68

90

40

Optimal renal dosing*
CCS

Yes
2

Yes
8

Yes
2

Yes
1

Yes
3

Yes
2

Yes
2

No
2

Mucositis

No

No

No

No

No

Yes

No

No

None

None

None

None

Cipro

SMX/TMP

Cipro

SMX/TMP

Sex

Prior prophylactic
antibiotic

8

Duration of neutropenia,
days
Concomitant Vancomycin

5

11

20

6

5

26

2

4

No

Yes

Yes

Yes

No

Yes

Yes

Yes

Concomitant GCSF

No

Yes

Yes

No

No

No

Yes

Yes

Abbreviations: CCS: Charlson Comorbidity Index Score; Cipro: ciprofloxacin; SMX/TMP: sulfamethoxazole/trimethoprim; GCSF:
granulocyte colony stimulating factor
*At the time of drug initiation
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Table 2: Diagnosis and current treatment
Patient number

Diagnosis

Chemotherapy regimen

1

Breast cancer

Docetaxel + cyclophosphamide

2

Burkitt’s lymphoma

Hyper-CVAD+R

3

B-cell ALL

Hyper-CVAD+R+MTX/ARA-C IT

4

Myasthenia gravis

N/A

5

AML

HiDAC

6

AML

7+3

7

Breast cancer

Docetaxel + cyclophosphamide

8

Kidney transplant

N/A

Abbreviations: Hyper-CVAD: cyclophosphamide, mesna, vincristine, doxorubicin, dexamethasone; R: rituximab; MTX+ARA-C:
methotrexate and cytarabine; IT: intrathecal; HiDAC: high dose cytarabine; 7+3 7 days of cytarabine and 3 days of idarubicin
Table 3: Patient Outcomes
Patient
number

1

2

3

4

5

6

7

8

Length of stay,
days

10

53

26

17

11

47

5

4

Readmission
for an
infectious
issue within
30 days

No

Inpatient
mortality

No

No

No

No

No

No

No

No

No

No

No

No

No

Study
number

No

No

Time to
defervescence,
hours

32

14

40.5

5.5

40

27

9.5

4

Duration of
antibiotics,
days

2

6

8.3

3

4.3

11

3

2

No

No

No

No

No

No

No

No

Antibiotic
failure

Table 4: Microbiologically documented infections
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1

Organism

Culture
site

Resistance

Clostridium difficile

Stool

Pansusceptible

2

Pseudomonas
aeruginosa

Abscess

Pansusceptible

3

N/A

4

Staphylococcus
aureus

Wound

Pansusceptible

5

N/A

6

Streptococcus
viridans

Blood

Pansusceptible

7

N/A

8

N/A
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DISCUSSION
Neutropenic fever is an oncologic emergency that requires swift
intervention with broad spectrum antibiotics. Meropenem is
commonly used for febrile neutropenia, especially as a step up
therapy
after
other
antibiotics
(e.g.
cefepime,
piperacillin/tazobactam) have failed or in patients at risk for or
with a history of resistant organisms. Previous literature has tried
to optimize meropenem dosing based on its pharmacokinetic
and pharmacodynamic profile. When compared to meropenem
1000 mg every 8 hours over 30 minutes, meropenem 500 mg
every 6 hours over 30 minutes achieved higher PTA for
susceptible pathogens in a pharmacokinetic study from 2005.8
Additionally, meropenem 500 mg every 6 hours administered
over 30 minutes produced similar outcomes to meropenem
1000 mg every 8 hours administered over 30 minutes in a study
applying population pharmacokinetic and Monte Carlo
simulations.9 A separate Monte Carlo simulation evaluated 1 g
of meropenem administered over either 30 minutes or 3 hours.3
When aiming for a time over the MIC of 40%, the PTA for
pathogens with a MIC of 4 was 75.7% with intermittent infusions
and 99.2% with extended infusions.3 When looking at the same
outcome for a MIC of 8, the study demonstrated a PTA of 17.8%
with intermittent infusions and 78.8% with extended infusions.3
This increased PTA is especially important for organisms
harboring resistance mechanisms, such as Pseudomonas
aeruginosa and Acinetobacter spp..3,10,11 The previously
mentioned Monte Carlo simulation also demonstrated a
marginal increase in PTA with extended infusions of meropenem
for both Pseudomonas aeruginosa (77.1% v. 79.3%) and
Acinetobacter spp. (75.8% v. 78%) infections.3 In the current
study, meropenem 500 mg every 6 hours infused over 3 hours
was administered to patients with febrile neutropenia.
Beta-lactam antibiotics have previously shown benefit in other
patient populations by extending the infusion time over a period
of three or four hours compared to a standard 30-minute
infusion.12-16 However, subgroup analyses of carbapenems have
not shown benefit in ICU patients or patients with pneumonia.1315,17 In a meta-analysis of continuous or extended infusions of
carbapenems or piperacillin/tazobactam for pneumonia or
infections in ICU patients, carbapenems did not significantly
reduce the risk of mortality (RR 0.66, 95% CI 0.34 – 1.30).13
Additionally, another meta-analysis of continuous or extended
infusions of beta-lactam antibiotics in ICU patients indicated
extended infusions of carbapenems did not reduce mortality (RR
0.74, 95% CI 0.42 – 1.28) or increase the rate of clinical success
(RR 1.16, 95% CI 0.93 – 1.46).14 In the same fashion, a metaanalysis of patients with nosocomial pneumonia receiving
continuous or extended infusions of anti-pseudomonal betalactam antibiotics showed no statistical increase in clinical cure
(OR 2.01, 95% CI 0.48 – 8.37) or statistical decrease in mortality
(OR 0.92, 95% CI 0.57-1.47) when using extended infusions of
carbapenems.15 Moreover, a meta-analysis of randomized
controlled trials including any hospitalized patient receiving
extended infusions of a beta-lactam antibiotic showed no
benefit for extended infusions in either mortality (RR 0.92, 95%
CI 0.61 – 1.37) or clinical cure (RR 1.00, 95% CI 0.94 – 1.06).17
Again, further subgroup analyses found no benefit with

extended infusions of carbapenems in regards to mortality (RR
1.08, 95% CI 0.64 – 1.82) or clinical cure (RR 1.00, 95% CI 0.92 –
1.10).17
In patients with febrile neutropenia, limited data exists
supporting the use of extended infusion beta-lactams or
carbapenems. A prospective study of febrile neutropenia
compared extended and intermittent infusions of cefepime 2 g
every 8 hours and observed no difference in defervescence at
24, 48, or 72 hours or time to defervescence.4 Only 63% of
patients receiving extended infusions of cefepime defervesced
at 48 hours and the median time to deferevescence was 19
hours. Of note, this prospective study only included hematologic
malignancies and stem cell transplant patients. Additionally,
patients were excluded if they met diagnostic criteria for sepsis
or had a creatinine clearance <50 mL/min. In a retrospective
study of cefepime extended infusions in oncology patients with
febrile neutropenia, those receiving extended infusions were
more likely to defervesce at 24 hours and time to defervescence
was decreased by 14 hours.5 Upon multivariate analysis, the
odds of defervescence at 24 hours were quadrupled with
extended infusions. Extended infusion piperacillin/tazobactam
was also studied prospectively in patients with febrile
neutropenia while undergoing hematopoietic stem cell
transplant or induction/consolidation therapy for acute
leukemia.6 In that study, extended infusion piperacillintazobactam increased the likelihood of overall response
(resolution of fever, sterile blood cultures, resolution of clinical
signs and symptoms, and no need for change in antibiotic
regimen) (74.4% extended infusion vs. 55.1% standard infusion,
p = 0.044).
In the only published study of extended infusion meropenem in
the setting of febrile neutropenia, patients undergoing
hematopoietic stem-cell transplantation or induction chemotherapy for AML were more likely to achieve treatment success
(resolution of fever for ≥ 24 h, resolution or improvement in
clinical signs and symptoms of infection, absence of persistent
or breakthrough bacteremia, and no additional antibiotics
prescribed) at 5 days if they received extended infusions (68.4%
extended infusion vs. 40.9% standard infusion, p<0.001).7 In
addition, patients receiving extended infusion meropenem had
a more prompt defervescence (p=0.021). In the current study,
extended infusions of meropenem appeared to be effective in
all eight patients. All patients defervesced within 48 hours of
meropenem administration and the median time to
defervescence was 20.5 hours. Additionally, no patients required
an escalation in antibiotic therapy, were readmitted for an
infectious issue within 30 days of discharge, or passed away
during their hospital stay. Although febrile neutropenia most
commonly occurs in the leukemic populations, patients in this
study had a variety of oncologic diagnoses including AML, ALL,
Burkitt’s lymphoma, and breast cancer. Furthermore, one patient
had myasthenia gravis and another was on chronic immunosuppression for a past kidney transplant. The variety of
diagnoses demonstrates that extended infusions of meropenem
may be effective in diverse patient populations who incur febrile
neutropenia. Additionally, four patients had a microbiologically
documented infection, one of which was Clostridium difficile and
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occurred while on day 2 of meropenem. No resistance patterns
were identified in any of the documented infections. Of note, in
the prior study of meropenem extended infusion, 55% of the
patients with microbiologically documented infections had
meropenem-resistant microorganisms compared to none in the
current descriptive study.7 To the authors’ knowledge, this is the
first description of meropenem extended infusion in the general
population with febrile neutropenia.

CONCLUSION
Febrile neutropenia has traditionally been treated with
intermittent infusions of beta-lactam antibiotics. Due to the
potential life-threatening nature of this oncologic complication,
it is important to identify effective interventions, including
optimal antibiotic administration techniques. In this descriptive
study, extended infusions of meropenem appeared to be
effective for the treatment of febrile neutropenia, without any
instances of antibiotic failure. Further comparative studies with
intermittent infusions in this general population of patients with
febrile neutropenia are warranted.
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